Literature DB >> 29891113

Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis.

M Arenas1, E Rodríguez2, A Sahebkar3, S Sabater4, D Rizo1, O Pallisé1, M Hernández1, F Riu5, J Camps6, J Joven7.   

Abstract

PURPOSE: Paraoxonase-1 (PON1) is a lipolactonase implicated in the elimination of carcinogenic free radicals and in the scavenging mechanisms to maintain oxidative balance. The objective of the present systematic review and meta-analysis was to evaluate possible alterations in serum PON1 activity in patients with cancer.
METHODS: A systematic search of the observational studies in humans published in the last 15 years was performed through Medline databases following the PRISMA and STARLITE statements. Further, a keyword-based computerized search with restrictions on publication date, and a meta-analysis of case-control studies was performed.
RESULTS: In total, 23 studies were included most of which reported decreased PON1 activity in patients with cancer. This could indicate impaired defense ability against oxidative stress with potential implications in cell proliferation, promotion of genetic instability, and alterations in cellular sensitivity to chemotherapy.
CONCLUSION: This systematic review and meta-analysis confirms a consistent association between cancer and decreased serum PON1 activities. These findings may open fruitful lines of research with clinical relevance, and an understanding of molecular alterations underlying carcinogenesis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Meta-analysis; Oxidative stress; paraoxonase-1

Mesh:

Substances:

Year:  2018        PMID: 29891113     DOI: 10.1016/j.critrevonc.2018.04.005

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  7 in total

1.  Association of Serum Paraoxonase 1 Activities, Polymorphisms and Oxidative Stress in Breast Cancer Patients with Type 2 Diabetes Mellitus.

Authors:  Fatma Ceyla Eraldemir; Nihal Üren; Tuğba Kum; Burcu Erbay; Deniz Şahin; Emel Ergül; Esra Acar; Doğa Özsoy; Mustafa Çekmen; Hale Kır; Zafer Utkan
Journal:  J Med Biochem       Date:  2019-05-11       Impact factor: 3.402

2.  Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab.

Authors:  Elizabeth W Thompson; Biniyam G Demissei; Amanda M Smith; Priya Brahmbhatt; Jessica Wang; Amy Clark; Angela DeMichele; Vivek Narayan; Payal Shah; Lova Sun; Benedicte Lefebvre; Michael G Fradley; Joseph R Carver; W H Wilson Tang; Bonnie Ky
Journal:  JACC Basic Transl Sci       Date:  2021-12-15

Review 3.  Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.

Authors:  Kush K Patel; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2021-06-12       Impact factor: 5.858

Review 4.  Paraoxonases Activities and Polymorphisms in Elderly and Old-Age Diseases: An Overview.

Authors:  Débora Levy; Cadiele Oliana Reichert; Sérgio Paulo Bydlowski
Journal:  Antioxidants (Basel)       Date:  2019-05-02

5.  Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates.

Authors:  Anita Bosak; Aljoša Bavec; Tilen Konte; Goran Šinko; Zrinka Kovarik; Marko Goličnik
Journal:  Molecules       Date:  2020-01-04       Impact factor: 4.411

Review 6.  A PON for All Seasons: Comparing Paraoxonase Enzyme Substrates, Activity and Action including the Role of PON3 in Health and Disease.

Authors:  Chrysan J Mohammed; Sabitri Lamichhane; Jacob A Connolly; Sophia M Soehnlen; Fatimah K Khalaf; Deepak Malhotra; Steven T Haller; Dragan Isailovic; David J Kennedy
Journal:  Antioxidants (Basel)       Date:  2022-03-19

7.  Association between inflammatory markers and serum paraoxonase and arylesterase activities in the general population: a cross-sectional study.

Authors:  Christa Meisinger; Dennis Freuer; Achim Bub; Jakob Linseisen
Journal:  Lipids Health Dis       Date:  2021-07-31       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.